IMMU-02. LOCOREGIONAL HER2CAR T CELLS FOR PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS: PRECLINICAL EFFICACY TO TOLERABILITY IN FIRST PATIENT
Nicholas A. Vitanza(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital), Juliane Gust(University of Washington), Jason S. Hauptman(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Julie Park(University of California, Los Angeles), Francisco A. Perez(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Navin Pinto(Seattle Children's Hospital), Rimas Orenta(Seattle Children's Hospital), Adam Beebe, Corrine Hoeppner(Seattle Children's Hospital), Adam Johnson(Sana Biotechnology (United States)), Laura S. Finn(Seattle Children's Hospital)
Cited by 2
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754